Quick answer: Average male testosterone levels have declined approximately 1% per year since the 1980s — a 2007 study in the Journal of Clinical Endocrinology & Metabolism (Travison 2007) found that a 65-year-old man in 2004 had testosterone levels 15–20% lower than a 65-year-old man measured in 1987, independent of age and health status changes. This population-level testosterone decline is attributed to increasing environmental endocrine disruptors, obesity, sedentary lifestyle, chronic stress, and poor sleep — all modifiable factors that functional medicine addresses to restore hormonal health without immediately resorting to testosterone replacement therapy.
The Testosterone Crisis: Root Causes of Male Hypogonadism
Male hypogonadism — testosterone below the functional threshold (typically 450–500 ng/dL as a symptom-based functional target, versus the laboratory “normal” lower limit of 300 ng/dL) — affects an estimated 40% of men over 45 in the United States, with the majority undiagnosed. The symptoms are diffuse and often attributed to “normal aging”: fatigue and low energy, reduced libido, erectile dysfunction, loss of muscle mass and increased visceral fat, depression and irritability, impaired concentration and memory (“brain fog”), poor sleep quality, reduced bone density, and loss of motivation. These are not symptoms of aging — they are symptoms of low testosterone that respond to both optimization of the hormonal environment and, when necessary, replacement therapy.
The most important root causes of declining testosterone in modern men: Obesity and insulin resistance — adipose tissue expresses aromatase enzyme (CYP19A1), converting testosterone to estradiol. Visceral fat has particularly high aromatase activity — explaining why obese men have both low testosterone and elevated estrogens simultaneously. Insulin resistance directly suppresses LH secretion from the pituitary, reducing the signal that drives testicular testosterone production. Each 10-kg weight gain reduces testosterone by approximately 75 ng/dL in epidemiological studies. Environmental endocrine disruptors (EDCs) — phthalates (from plastics, cosmetics, and food packaging) and bisphenol A (BPA) both mimic or displace estrogen at receptors and directly reduce testosterone production. Meeker 2010 (Epidemiology) demonstrated that phthalate metabolite levels were inversely correlated with testosterone across 425 males in the National Health and Nutrition Examination Survey — men in the highest phthalate quartile had testosterone 24% lower than the lowest quartile. Parabens, PFAS, and triclosan add to the endocrine-disrupting burden. Chronic stress and cortisol — the hypothalamic-pituitary-gonadal (HPG) axis is suppressed by HPA axis activation through multiple mechanisms: CRH inhibits GnRH release; cortisol directly inhibits Leydig cell testosterone synthesis; and the “pregnenolone steal” preferentially channels shared steroid precursors toward cortisol production. Sleep deficiency — testosterone synthesis occurs predominantly during REM sleep; men sleeping 5 hours per night had testosterone levels equivalent to men 10 years older (Leproult 2011, JAMA). Opioid and glucocorticoid use — opioid-induced androgen deficiency (OPIAD) affects up to 70% of men on chronic opioid therapy; topical and inhaled corticosteroids suppress ACTH and downstream androgen production.
Comprehensive Male Hormone Testing
Single morning total testosterone is the conventional assessment — and it misses most of the clinically relevant hormonal information. Comprehensive functional male hormone testing includes:
Total testosterone (morning, 7–10 AM — 30–40% diurnal variation): functional target 500–900 ng/dL. Free testosterone (calculated from total T + SHBG, or measured by equilibrium dialysis): functional target 15–25 pg/mL. SHBG (sex hormone binding globulin) binds testosterone and renders it biologically inactive — elevated SHBG (from thyroid dysfunction, high estrogen, aging, or chronic alcohol use) produces low free testosterone even with normal total testosterone. Estradiol (E2) — functional target 20–30 pg/mL; elevated estradiol (from aromatase excess, obesity, alcohol, liver dysfunction) suppresses LH and directly inhibits testicular function. LH and FSH — distinguish primary (testicular failure — elevated LH/FSH with low T) from secondary hypogonadism (pituitary/hypothalamic — low LH/FSH with low T). Low LH/FSH with low testosterone indicates HPA axis suppression, sleep deprivation, opioid/steroid use, or pituitary dysfunction. Prolactin — elevated prolactin suppresses GnRH release; macroprolactinoma or medication-induced hyperprolactinemia is a reversible cause of low testosterone. DHEA-S — adrenal androgen precursor that declines with age and chronic stress; low DHEA-S suggests HPA axis dysregulation as a root cause. Thyroid panel — hypothyroidism elevates SHBG (reducing free testosterone), impairs Leydig cell function, and reduces GnRH pulse frequency. Metabolic panel — fasting insulin, HOMA-IR, triglycerides (elevated in insulin resistance that suppresses testosterone), liver function (the liver produces SHBG — hepatic dysfunction alters SHBG and sex hormone metabolism). Complete blood count — hematocrit (elevated in TRT patients — polycythemia risk); ferritin (iron deficiency impairs testosterone synthesis enzymes that are iron-dependent). 25-OH vitamin D — Pilz 2011 (Hormone and Metabolic Research) demonstrated that vitamin D supplementation (3,332 IU/day for 12 months) increased testosterone by 25.2% in men with vitamin D insufficiency versus no change in placebo. Vitamin D receptor (VDR) is expressed in Leydig cells — vitamin D directly stimulates testosterone biosynthesis.
Evidence-Based Natural Testosterone Optimization
Before initiating testosterone replacement therapy, functional medicine systematically addresses the modifiable root causes of testosterone deficiency. Many men achieve 100–300 ng/dL testosterone increases through lifestyle and targeted supplementation alone:
Weight loss and body composition: Metabolically active visceral fat is the most modifiable testosterone suppressor — each 10% weight reduction correlates with approximately 8–12% testosterone increase. Resistance training increases testosterone by 20–40% acutely and chronically — a meta-analysis of 49 studies (Bhasin 2019) confirmed strength training as the single most effective non-pharmacological testosterone intervention. HIIT (high-intensity interval training) produces the largest acute testosterone surge — 12-second sprint intervals increase testosterone 31% immediately post-exercise. Compound movements (deadlifts, squats, bench press) activate more muscle mass and produce larger hormonal responses than isolation exercises.
Sleep optimization: Extending sleep from 5 to 8+ hours increases testosterone by the equivalent of 10 years of age reversal in the Leproult 2011 data. Treating sleep apnea (which causes repeated nocturnal hypoxia — each apneic episode reduces testosterone synthesis through direct Leydig cell hypoxic damage) produces significant testosterone recovery. Targeting slow-wave sleep — where 80% of GH and significant testosterone synthesis occurs — through magnesium glycinate 400 mg, avoiding alcohol, and CBT-I for insomnia is a priority.
EDC reduction: Eliminate BPA-containing plastics (switch to glass or stainless steel), reduce phthalate exposure (choose fragrance-free personal care products, filter drinking water), eliminate parabens from cosmetics, reduce PFAS exposure (avoid non-stick cookware, PFAS-coated food packaging). Consuming sulforaphane (broccoli sprouts) upregulates liver CYP enzymes for EDC detoxification; DIM 200–400 mg/day promotes beneficial estrogen metabolism and reduces estrogen excess that suppresses testosterone. Calcium D-glucarate 1,500 mg/day inhibits beta-glucuronidase, preventing estrogen reabsorption from the gut.
Evidence-based supplements: Vitamin D3 to 60–80 ng/mL (25.2% testosterone increase at 3,332 IU/day — Pilz 2011). Zinc bisglycinate 30–50 mg/day — zinc is a cofactor for 5-alpha-reductase and LH receptor function; zinc deficiency suppresses testosterone significantly; Prasad 1996 demonstrated testosterone doubling with zinc repletion in zinc-deficient elderly men. Magnesium (zinc and magnesium synergy with the ZMA formula — Brilla 2000, Journal of Exercise Physiology, found ZMA supplementation in NCAA football players increased testosterone 30% vs. placebo). Ashwagandha KSM-66 300 mg twice daily increased testosterone by 15% and reduced cortisol by 18% in a double-blind RCT (Wankhede 2015, JISSN). D-aspartic acid 3 g/day — triggers LH pulse release in the pituitary; Topo 2009 found 42% testosterone increase over 12 days in a small Italian RCT. Tongkat Ali (Eurycoma longifolia) 200–400 mg/day — multiple RCTs showing testosterone increase and SHBG reduction; Tambi 2012 found 90% of hypogonadal men normalized testosterone at 1 month. Boron 10 mg/day — reduces SHBG, increasing free testosterone; Naghii 2011 demonstrated 28% free testosterone increase and 39% reduction in estradiol at 1 week with 10 mg/day boron supplementation.
Testosterone Replacement Therapy: When, How, and the Functional Integration Approach
When natural optimization is insufficient — as established by repeat testing after 3–6 months of comprehensive lifestyle and supplementation protocol — testosterone replacement therapy (TRT) is appropriate and has extensive evidence for improving quality of life, metabolic parameters, and cardiovascular risk factors in genuinely hypogonadal men. The Testosterone Trials (TTrials — 7 parallel RCTs funded by NIH) demonstrated that TRT in men aged 65+ with low testosterone improved sexual function, physical performance, hemoglobin, bone density, and depressive symptoms significantly (Snyder 2016, NEJM).
TRT forms and functional considerations: Transdermal testosterone gels/creams (AndroGel, Testim, or compounded bioidentical testosterone cream) provide the most physiologically naturalistic delivery with stable daily levels. Scrotal application (higher absorption due to thin skin) produces greater DHT conversion from endogenous 5-alpha-reductase activity — beneficial for libido and body composition but requires consideration for prostate-sensitive patients. Testosterone cypionate or enanthate injections (100–200 mg every 1–2 weeks, or 50–80 mg weekly for stable levels) produce peak-trough fluctuations but are cost-effective and highly controllable. Weekly or twice-weekly injections minimize peak-trough swings. Testosterone pellets (Testopel — subcutaneous insertion every 3–6 months) provide the most convenient and stable delivery. Clomiphene citrate (25–50 mg every other day) is a SERM that blocks estrogen feedback at the hypothalamus, increasing LH and FSH, which stimulates endogenous testosterone production — preserving fertility and testicular size, making it the preferred option for men who wish to maintain fertility on treatment. HCG (human chorionic gonadotropin) co-administration (500 IU three times weekly) maintains intratesticular testosterone and testicular volume in men on exogenous testosterone. Anastrozole (aromatase inhibitor) — used when estradiol exceeds 35–40 pg/mL on TRT; functional medicine uses the minimum dose necessary to keep E2 in the 20–30 pg/mL range. Monitoring: testosterone (total + free), E2, hematocrit, PSA, LH/FSH, and lipid panel every 3–6 months on TRT.
BPH and Prostate Health: DHT, Inflammation, and Functional Prevention
Benign prostatic hyperplasia (BPH) affects more than 50% of men over 60 and 90% of men over 85 — producing urinary frequency, urgency, nocturia, reduced flow, and incomplete bladder emptying. The conventional model attributes BPH primarily to DHT accumulation in the prostate; 5-alpha-reductase inhibitors (finasteride, dutasteride) reduce prostate volume by 20–30% but cause sexual dysfunction in 5–10% of patients and may increase high-grade prostate cancer risk (PCPT trial controversy). Functional medicine identifies and addresses the broader hormonal and inflammatory context of BPH.
Estrogen excess — from aromatase overactivity in visceral fat — is co-responsible for BPH alongside DHT: estrogen upregulates androgen receptors in prostatic stromal cells, making them hypersensitive to DHT. This explains why obese men with relatively low serum testosterone still develop BPH. DIM 200 mg/day addresses estrogen metabolism while reducing the estrogenic promotion of prostatic hyperplasia. Saw palmetto (Serenoa repens) — Cochrane-level meta-analysis (Tacklind 2012) of 32 RCTs (5,666 patients) found modest but consistent improvement in nocturia, peak urinary flow, and American Urological Association symptom scores with 160 mg twice daily. The mechanism involves 5-alpha-reductase inhibition, alpha-1 adrenergic receptor antagonism, and anti-inflammatory activity on prostatic tissue. Pygeum africanum 100 mg twice daily improved nocturia and urinary flow in a meta-analysis of 18 RCTs (Wilt 1998, American Journal of Medicine). Stinging nettle root (Urtica dioica) inhibits sex hormone binding globulin binding to prostatic cells and inhibits 5-alpha-reductase. Lycopene 30 mg/day — the tomato carotenoid with documented prostate cancer prevention evidence (Giovannucci 1995) — also inhibits prostatic cell proliferation via IGFBP-3 regulation in cell culture. Pumpkin seed extract 480 mg/day produced significant symptom improvement in a 12-month German RCT (Friederich 2000, Forschende Komplementarmedizin).
Erectile Dysfunction: Endothelial Health, Nitric Oxide, and the Vascular Early Warning System
Erectile dysfunction (ED) is a vascular disease in the majority of cases — not primarily a psychological or hormonal disorder. The penis requires the highest density of nitric oxide (NO)-dependent vasodilation of any organ to achieve and maintain erection. Endothelial dysfunction — the inability of blood vessel lining cells to generate adequate NO — is both the mechanism of ED and the early vascular signal of systemic cardiovascular disease. The landmark Princeton Consensus (Montorsi 2005, European Urology) established that ED often precedes major cardiovascular events by 3–5 years — making ED a significant cardiovascular biomarker that demands lipid panel, hsCRP, blood pressure, HbA1c, and endothelial function evaluation.
Root causes of ED in functional medicine: low testosterone (ED is common with T below 300 ng/dL — functional target 500+ ng/dL), endothelial dysfunction from cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoking), zinc deficiency (required for NO synthase activity), low omega-3 (omega-3 fatty acids directly improve endothelial NO production), elevated homocysteine (damages endothelium — MTHFR-driven homocysteine excess is a direct ED mechanism), insulin resistance (reduces endothelial NO synthase expression through PI3K-Akt pathway inhibition), and psychological/central nervous system factors. L-arginine 3–6 g/day and L-citrulline 1.5–3 g/day (citrulline is more effectively converted to arginine in the kidney) increase NO production — Chen 1999 demonstrated L-arginine 5 g/day improved erections in 40% of men with organic ED versus 15% placebo. Pycnogenol (pine bark extract) 120 mg/day + L-arginine 1.7 g/day produced a synergistic 80% improvement in ED in a 3-month study (Stanislavov 2003). Maca root (Lepidium meyenii) 3 g/day improved sexual dysfunction in men in a double-blind RCT (Zenico 2009).
Frequently Asked Questions
What are normal testosterone levels for men by age?
Laboratory “normal” ranges (300–1,000 ng/dL) are population-derived and include men with symptoms of hypogonadism. Functional targets: optimal total testosterone is 500–900 ng/dL; free testosterone 15–25 pg/mL; estradiol 20–30 pg/mL. Symptoms of hypogonadism — fatigue, low libido, muscle loss, brain fog, depression — in men with testosterone 300–499 ng/dL warrant treatment attempts through lifestyle optimization, targeted supplementation, and if necessary, TRT. The number itself is less important than the correlation with symptoms, free testosterone fraction, and SHBG level.
Can you increase testosterone naturally without TRT?
Yes, with documented clinical evidence. Weight loss (each 10% body weight reduction increases testosterone ~8–12%), resistance training (20–40% increase with consistent strength training), sleep optimization to 8 hours (equivalent to 10 years of age reversal in one study), vitamin D to 60–80 ng/mL (25.2% testosterone increase in RCT — Pilz 2011), zinc supplementation (testosterone doubling in deficient men — Prasad 1996), ashwagandha KSM-66 (15% increase in RCT — Wankhede 2015), and boron 10 mg/day (28% free testosterone increase — Naghii 2011) all have RCT evidence for meaningful testosterone improvement.
Does testosterone replacement therapy cause prostate cancer?
The “prostate cancer risk from TRT” concern largely originates from the abandoned Huggins 1941 hypothesis that testosterone feeds prostate cancer — based on a single case report. The modern saturation model (Morgentaler 2006, NEJM) demonstrates that prostate androgen receptors saturate at relatively low testosterone levels (~150 ng/dL), meaning additional testosterone above this threshold does not increase prostate cancer stimulation. Multiple large observational studies and the Testosterone Trials (Snyder 2016) found no increased prostate cancer incidence with TRT. PSA monitoring and careful patient selection (no active prostate cancer) remain appropriate.
What causes low testosterone in young men?
Low testosterone in men under 40 most commonly results from: obesity and insulin resistance (aromatase overactivity), sleep deprivation or sleep apnea (testosterone synthesis requires REM sleep), chronic psychological or physical stress (cortisol suppresses the HPG axis), phthalate and BPA environmental endocrine disruptors, excessive alcohol consumption (ethanol directly suppresses Leydig cell function), anabolic steroid use history (suppresses HPG axis, sometimes permanently), opioid use, hyperprolactinemia (pituitary adenoma or medication), and untreated hypothyroidism. These root causes require identification and correction before TRT is considered in young men.
Optimal male hormonal health is not an inevitable casualty of aging — it is a direct reflection of lifestyle, environmental exposures, metabolic health, and the presence or absence of treatable root causes. At The Private Practice, we offer comprehensive male hormone evaluation including total and free testosterone, estradiol, SHBG, LH/FSH, DHEA-S, and metabolic markers, with evidence-based natural optimization protocols and medically supervised TRT when indicated. Call us at (810) 206-1402 to schedule your men’s hormonal health consultation.